Y-mAbs Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Y-mAbs Therapeutics's estimated annual revenue is currently $46M per year.
- Y-mAbs Therapeutics's estimated revenue per employee is $422,477
- Y-mAbs Therapeutics's total funding is $338.8M.
- Y-mAbs Therapeutics's current valuation is $529M. (January 2022)
Employee Data
- Y-mAbs Therapeutics has 109 Employees.
- Y-mAbs Therapeutics grew their employee count by -32% last year.
Y-mAbs Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Associate Medical Director | Reveal Email/Phone |
2 | Senior Medical Director | Reveal Email/Phone |
3 | Senior Data Manager | Reveal Email/Phone |
4 | Strategic Account Manager - West | Reveal Email/Phone |
Y-mAbs Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $80.9M | 373 | 27% | $125M | N/A |
What Is Y-mAbs Therapeutics?
Y-mAbs is late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates - naxitamab and omburtamab - which target tumors that express GD2 and B7-H3, respectively. Our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. With the right partnerships and collaboration, we envision expanding our capabilities to treat adults - changing the course of cancer and its outcome.
keywords:N/A
$338.8M
Total Funding
109
Number of Employees
$46M
Revenue (est)
-32%
Employee Growth %
$529M
Valuation
N/A
Accelerator
Y-mAbs Therapeutics News
Amber Tong. Senior Editor. Over the past seven years, Claus Moller helped steer Y-mAbs Therapeutics from a secretive Danish biotech startup...
Y-mAbs Therapeutics Inc's · Thomas Gad, the Company's Founder, Chairman & President, has assumed the interim CEO and Board Member role.
Y-mAbs Therapeutics (NASDAQ:YMAB) said Wednesday CEO Claus Moller stepped down from his role and as board member, effective immediately.
Y-mAbs Therapeutics, Inc., a NYC-based immunotherapy company discovering and developing innovative treatments for patients with cancer, completed an extended closing of an additional $30m in a private equity placement. It added institutional investors Sofinnova Ventures and Scopia Capital Manag ...
Y-mAbs Therapeutics, Inc., a New York-based immunotherapy company discovering and developing innovative treatments for patients with cancer, closed a $50m equity financing. The round was led by HBM Healthcare Investments (HBM) with support from current shareholders. The funding will enable YmA ...
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $15.8M | 109 | -10% | $42M |
#2 | $22.9M | 109 | -6% | N/A |
#3 | $3.5M | 109 | 21% | N/A |
#4 | $15.8M | 109 | -2% | $53.6M |
#5 | $7.5M | 109 | 7% | N/A |